Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study.
about
Anticancer effects of the nitric oxide-modified saquinavir derivative saquinavir-NO against multidrug-resistant cancer cellsExploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunitiesRole of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistanceThe clinically relevant pharmacogenomic changes in acute myelogenous leukemiaSynthesis of a dual functional anti-MDR tumor agent PH II-7 with elucidations of anti-tumor effects and mechanismsTargeting multidrug resistance in cancerRandomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421.Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemiaAre MTT assays the right tool to analyze drug resistance caused by ABC-transporters in patient samples?ABC transporters and drug resistance in leukemia: was P-gp nothing but the first head of the Hydra?Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML).Southwestern Oncology Group pretreatment risk criteria as predictive or prognostic factors in acute myeloid leukemiaMechanism Underlying the Reversal of Drug Resistance in P-Glycoprotein-Expressing Leukemia Cells by Pinoresinol and the Study of a DerivativeP-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPAClofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia.The co-delivery of a low-dose P-glycoprotein inhibitor with doxorubicin sterically stabilized liposomes against breast cancer with low P-glycoprotein expression.Unsuccessful diagnostic cytogenetic analysis is a poor prognostic feature in acute myeloid leukaemia.Challenges in treating older patients with acute myeloid leukemia.New positron emission tomography tracer [(11)C]carvedilol reveals P-glycoprotein modulation kinetics.P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype.Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia.Mdr1 gene expression and mutations in Ras proto-oncogenes in acute myeloid leukemia.Molecular pathways: regulation and therapeutic implications of multidrug resistanceZosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens.Acute myeloid leukemia: treatment of adults under 60 years.Acute myeloid leukemia: treatment over 60.Treatment of refractory and relapsed acute myelogenous leukemia.Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug ResistanceThe prognostic significance of IRF8 transcripts in adult patients with acute myeloid leukemiaOverview of the clinical efficacy of investigational anticancer drugs.ATP Binding Cassette transporters associated with chemoresistance: transcriptional profiling in extreme cohorts and their prognostic impact in a cohort of 281 acute myeloid leukemia patientsStrategies for reversing drug resistance.Management of acute myelogenous leukemia in the elderly.Analysis of the interaction of induction regimens with p-glycoprotein expression in patients with acute myeloid leukaemia: results from the MRC AML15 trial.Reversal of MDR by verapamil analogues.P glycoprotein in human immunodeficiency virus type 1 infection and therapy.Diagnosis, complications and management of chronic neutrophilic leukaemia: A case reportEfficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice.
P2860
Q24628715-CB63B4AC-CD5F-4620-8B9A-82F26798FFFEQ26828930-62F58156-AE4B-4E4C-8C53-C6B61B6C35ACQ26865927-6254910E-3F73-447F-993E-82F834E2E101Q27014790-9CB4D504-9AF9-42FB-9E1E-74279F79392AQ28481389-F35A860E-B4A9-4316-8E88-FA0B081DA40EQ29616803-6ED0AA47-D3E0-4FD5-99F3-290A9F49FAB5Q30444746-7255736E-0D0E-4DED-86A7-571B0CDA1EAAQ30497200-232AD6BF-6E1A-4106-ADB8-3D6ECFC691F4Q33221958-D72DDEF6-7F1D-461E-892D-4E61C061E193Q33281867-845FF119-CD99-4DB8-A05E-0E77EE99890FQ33319637-0BB7D918-5538-40CD-A997-AA881BD8712AQ33598706-0E8FF6FC-3469-4B64-8E80-193FAC3A5C2AQ33600323-F5E7A185-40EF-4A9F-B9B2-A6DC6931BBEFQ33934534-EB5D259F-4038-443E-B15E-ADF165391537Q33949752-312542D7-51F2-4997-B8AE-BC11C6EFB174Q33961526-FED3F7E3-3FFE-4837-9F9C-3EA648613AF1Q33981864-34F197C4-9BF8-43DB-B409-37F1FA813FE3Q33985549-E1D17514-5974-4007-91DD-F71E229C51C4Q33987752-F62D1C6D-D67D-4900-AB8C-A9E8C5BFC04DQ34124919-FA540DBB-6BBE-4915-8B92-5563649C98C1Q34142289-CF9A8AD2-E9DF-464D-B5EF-0FEF6C59C099Q34154708-843C158A-0A60-4B8B-A5AA-ECA70A99F730Q34155343-95138A58-9EE2-42EB-886B-D9DE9B4D3B35Q34255292-3CBC91F1-A013-48D9-A4C5-943A9AEDE3E0Q34360283-E4478DBD-19EE-4827-975D-7C7E24B269D5Q34591403-01DE5468-14EE-4417-88F9-18BAECD470DCQ34680933-BD0F9CA1-CB90-429C-AB09-794537626522Q34680938-AB99D1C3-AB20-4B60-B007-C20E61AB2E9FQ34734034-AA008C3F-AE57-4DC6-BDC1-C3119B015582Q34774854-6CD0150D-8A29-44E8-B429-822054DAF970Q34962889-E1C642F6-441E-4CB3-A78B-915F8F9CFB60Q35067125-5C0EC240-E494-4D96-A2FC-78D7C25BA059Q35193725-4579C4D7-7F4D-46FD-8EE3-EE163B4E27C6Q35567287-CB65BC7F-AC0E-46AB-88A1-F549843F075FQ35599067-4B640E3E-8851-4A51-9B69-F8FF9F2FC620Q35664332-41E62D1A-8A88-4486-B318-A684B77353D2Q35668684-B1AD7960-7FC9-4991-B7B1-E3A24D9A54EBQ35718765-25FF4302-9ADA-41E0-B350-2A0C7D28FA75Q35758855-C4D66B6D-86B2-4B33-95DB-4E916DECDCE5Q35800831-52130FC5-F83E-4EB5-BFDA-E6B912C9EB8E
P2860
Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Benefit of cyclosporine modula ...... outhwest Oncology Group study.
@en
Benefit of cyclosporine modula ...... outhwest Oncology Group study.
@nl
type
label
Benefit of cyclosporine modula ...... outhwest Oncology Group study.
@en
Benefit of cyclosporine modula ...... outhwest Oncology Group study.
@nl
prefLabel
Benefit of cyclosporine modula ...... outhwest Oncology Group study.
@en
Benefit of cyclosporine modula ...... outhwest Oncology Group study.
@nl
P2093
P1433
P1476
Benefit of cyclosporine modula ...... outhwest Oncology Group study.
@en
P2093
Doroshow JH
Kopecky KJ
Persons DL
P304
P356
10.1182/BLOOD.V98.12.3212
P407
P577
2001-12-01T00:00:00Z